Skip to main content

Table 1 Baseline disease characteristics of 210 patients with axial spondyloarthritis

From: Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort

Baseline parameters Nr-axSpA (n = 95) AS (n = 115) All patients (n = 210)
Age, years 38.7 ± 9.9 36.8 ± 11.0 37.3 ± 10.6
Male gender, n (%) 32 (33.7) 75 (65.2) 107 (51.0)
HLA-B27 positive, n (%) 69 (72.6) 97 (84.3) 166 (79.0)
Duration of symptoms, years 3.2 ± 2.2 5.2 ± 2.8 4.2 ± 2.7
BASDAI, points NRS (0–10) 4.2 ± 2.0 3.8 ± 2.2 3.9 ± 2.2
Peripheral arthritis, n (%) 16 (16.8) 15 (13.0) 31 (14.8)
BASFI, points NRS (0–10) 2.8 ± 2.2 3.0 ± 2.4 2.9 ± 2.3
BASMI, points (0–10) 1.5 ± 1.5 2.0 ± 1.7 1.8 ± 1.6
CRP, mg/l 6.5 ± 12.8 12.4 ± 16.6 9.7 ± 15.2
mSASSS, points (0–72) 2.3 ± 4.2 5.9 ± 10.3 4.2 ± 8.3
NSAIDs intake, n (%) 64 (67.4) 76 (66.1) 140 (66.7)
Systemic steroids intake, n (%) 6 (6.3) 6 (5.2) 12 (5.7)
DMARDs intake, n (%) 26 (27.4) 35 (30.4) 61 (29.0)
TNFα blocker intake, n (%) 1 (1.1) 4 (3.5) 5 (2.4)
Current smoking, n (%) 24 (25.3) 39 (33.9) 63 (30.0)
  1. Continuous variables are presented as mean ± standard deviation
  2. AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, DMARDs disease-modifying anti-rheumatic drugs, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, nr-axSpA non-radiographic axial spondyloarthritis, NRS numeric rating scale, NSAIDs non-steroidal anti-inflammatory drugs, TNFα tumour necrosis factor alpha